Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

Regeneron

A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In Combination With Linvoseltamab, An Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, In Participants With Relapsed/Refractory Multiple Myeloma. (NCT06669247)

Currently recruiting

PROBE

A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (NCT04986865)

Currently recruiting

RLY-2608-101

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer (NCT05216432)

Currently recruiting

POLARIS1

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Imatinib Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (NCT06051409)

Currently recruiting

CLOU064A2304

A global, multicenter, randomized, double-blind, doubledummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines (NCT06042478)

Currently recruiting

AP-0103

A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (AP-0103) (NCT05789537)

Recently completed/closed

AP-0102

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (AP-0102) (NCT05789524)

Recently completed/closed

FILGOTINIB 3899

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis (NCT02914535)

Currently recruiting

NIMBLE-AZD0466

A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419)

Currently recruiting

EMITT-1 GREY WOLF

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies (ACTRN12623000108617)

Currently recruiting

MonumenTAL-2

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma (NCT05050097)

Currently recruiting

PETRANHA

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) (NCT05367440)

Currently recruiting

SPK-8011-8016-LTFU

A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males with Hemophilia A (NCT03432520)

Currently recruiting

The STOP-MED CTRCD Trial

A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial (NCT06183437)

Currently recruiting

DIRECT/InspIRE Australia

A multi-centre, open-label innovation study in pancreatic cancer utilising Nanoknife® System for Irreversible Electroporation (IRE) in unresectable stage 3 pancreatic adenocarcinoma (ACTRN12621000955819)

Currently recruiting

MND-PLL001

A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo-controlled Study with an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of Subjects with Amyotrophic Lateral Sclerosis (NCT06513546)

Currently recruiting

RAPID STUDY

A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)

Currently recruiting

FORMaT

A multi-centre, randomised, multi-arm, adaptive platform trial in people with or without cystic fibrosis Finding the Optimal Regimen for Mycobacterium abscessus Treatment [FORMaT] (NCT04310930)

Currently recruiting

Bi 1368-0140

A multi-centre, randomised, placebo-controlled, doubleblind, parallel-group trial to evaluate safety and efficacy of spesolimab [BI 655130] in adult patients with ulcerative pyoderma gangrenosum [PG] who require systemic therapy (NCT06624670)

Currently recruiting

EMBOCUBE

A Multicenter Observational Study to Evaluate Outcomes of EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging (NCT05307783)

Recently completed/closed
1 2 3 4